Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10387257 | 1.00 | MAPT (0.46) | MAPTNPSR1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4539662 | 1.00 | MAPT (0.46) | MAPTNPSR1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3183430 | 0.88 | MAPT (0.55) | MAPTNPSR1LMNAKMT2ACA1 | |
| SCHEMBL3194980 | 0.88 | MAPT (0.55) | MAPTNPSR1LMNAKMT2ACA1 | |
| SCHEMBL822823 | 0.87 | KMT2A (0.47) | MAPTNPSR1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7270580 | 0.85 | MAPT (0.43) | MAPTNPSR1LMNACA1CA2 | |
| SCHEMBL10865691 | 0.85 | MAPT (0.43) | MAPTNPSR1LMNACA1CA2 | |
| SCHEMBL10853348 | 0.84 | LMNA (0.52) | MAPTNPSR1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL10853353 | 0.84 | LMNA (0.52) | MAPTNPSR1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7984000 | 0.84 | SMN1; SMN2 (0.42) | NPSR1LMNASMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| EP-2638007-A2 | DRUG DERIVATIVES | Redx Pharma Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012123966-A1 | PROCESS FOR THE PREPARATION OF 4 -SUBSTITUTED -1, 4-DIHYDROPYRIDINES | ARCH PHARMALABS LIMITED (IN) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| US-4707486-A | Diaryl piperidine containing esters of 1,4-dihydropyridines and coronary therapeutic use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-11-17 | — | — | US | disclosed |
| US-4670449-A | HYPOTENSIVE AGENTS | PFIZER INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4661485-A | 2-pyrimidylaminoalkoxymethyl-6-methyl-3,5-bis (alkoxycarbony-1)-1,4-dihydropyridine antihypertensive agents | PFIZER INC. (US) | 1987-04-28 | — | — | US | disclosed |
| US-4621082-A | Pyridopyrimidines, pharmaceutical compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-04 | — | — | US | disclosed |
| US-4616024-A | Dihydropyridine anti-ischaemic and antihypertensive agents | PFIZER INC. (US) | 1986-10-07 | — | — | US | disclosed |
| US-4600778-A | Process for the preparation of 1,4-dihydropyridinedicarboxylic esters | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0100189-B1 | DIHYDROPYRIDINE ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1986-05-28 | — | — | EP | disclosed |
| US-4572908-A | HYPOTENSIVE AND ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1986-02-25 | — | — | US | disclosed |
| US-4515799-A | Dihydropyridine anti-ischaemic and antihypertensive agents | PFIZER INC. (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0100189-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | MAPT 1762/4885NPSR1 1805/4885LMNA 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.